Xenon Pharmaceuticals XENE Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$345.91M-47.6% | -$234.33M-28.5% | -$182.39M-45.5% | -$125.37M-58.9% | ||
| $2.54M-0.7% | $2.56M— | —— | $1.41M+55.1% | ||
| $53.71M+5.9% | $50.72M+56.7% | $32.37M+58.9% | $20.38M+103% | ||
| -$279.12M-53.9% | -$181.39M-20.0% | -$151.11M-49.6% | -$101.03M-45.4% | ||
| $799K-74.0% | $3.08M-45.3% | $5.62M+94.1% | $2.89M+41.2% | ||
| $218M+32.1% | $165M+248% | -$111.39M+62.2% | -$294.72M— | ||
| $117.11M+865% | $12.13M— | —— | $278.47M-37.8% | ||
| $56.45M— | —— | $96.36M+181% | -$118.45M-187% | ||
| -$279.92M-51.7% | -$184.46M-17.7% | -$156.73M-50.8% | -$103.92M-45.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Xenon Pharmaceuticals's cash flow data come from?
- Every line is extracted from Xenon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.